Multicenter Phese II Study of SOX plus Bevacizumab Therapy with Oxaliplatin Stop-and-Go Strategy and Oral S-1 plus Bevacizumab Maintenance Therapy in Advanced Colorectal CancerC - CCOG1002.1

Chubu Clinical Oncology Group0 个研究点目标入组 40 人开始时间: 2013年9月8日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Previous history of severe drug-induced allergy. 2) Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers, and man who wish to become his partner pregnancy. 3) Uncontrolled infection. 4) Uncontrolled severe complications (Interstitial lung disease, pulmonary fibrosis, renal failure, liver failure, DM, hypertension, et al.). 5) Patient with symptomatic cardiovascular disease or asymptomatic disease. 6) Patient who have peripheral nerve disorder. 7) Patient who have severe diarrhea. 8) Massive pleural effusion or ascites that required drainage. 9) Brain metastasis 10) History of Interstitial lung disease. 11) History of active double cancer. 12) Systemic administration of steroid. 13) Contraindication of S-1, L-OHP, Bevacizumab. 14) Not appropriate for the study at the physician's assessment. 15) Patient receiving surgical procedure within 28days. 16) History of gastrointestinal perforation within 6 months. 17) Patient who have gastrointestinal ulcer or bleeding. 18) Diathesis of bleeding or coagulopathy. 19) History of thoromboembolitic disease. 20) Patient with untreated traumatic bone fracture. 21) Systemic administration of antiplatelet drug, aspirin, and NSAIDS. 22) History of hemoptysis. 23) Colorectal cancer with obstruction. 24) Peritoneum dissemination confirmed by imaging

发起方

Chubu Clinical Oncology Group